blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2622351

EP2622351 - NEUROPEPTIDE Q AS MODULATOR OF GPCR GALR2 AND USES THEREOF [Right-click to bookmark this link]
Former [2013/32]NEUROPEPTIDE Q AS MODULATOR OF GPCR GALR2 AND USES THEREOF
[2014/12]
StatusNo opposition filed within time limit
Status updated on  03.07.2015
Database last updated on 05.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Actelion Pharmaceuticals Ltd.
Gewerbestrasse 16
4123 Allschwil / CH
[2013/32]
Inventor(s)01 / LEROY, Xavier
c/o Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil / CH
 [2013/32]
Representative(s)Gschwend, Thomas Peter, et al
Actelion Pharmaceuticals Ltd.
Legal Department
Gewerbestrasse 16
4123 Allschwil / CH
[N/P]
Former [2013/32]Gschwend, Thomas Peter, et al
Actelion Pharmaceuticals Ltd. Legal Department Gewerbestrasse 16
4123 Allschwil / CH
Application number, filing date11773875.723.09.2011
WO2011IB54205
Priority number, dateWO2010IB5436928.09.2010         Original published format: PCT/IB2010/054369
[2013/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012042455
Date:05.04.2012
Language:EN
[2012/14]
Type: A1 Application with search report 
No.:EP2622351
Date:07.08.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 05.04.2012 takes the place of the publication of the European patent application.
[2013/32]
Type: B1 Patent specification 
No.:EP2622351
Date:27.08.2014
Language:EN
[2014/35]
Search report(s)International search report - published on:EP05.04.2012
ClassificationIPC:G01N33/566
[2013/32]
CPC:
G01N33/566 (EP,US); G01N2333/5755 (EP,US); G01N2500/02 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/32]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NEUROPEPTID Q ALS GPCR-GALR2-MODULATOR UND SEINE VERWENDUNG[2014/17]
English:NEUROPEPTIDE Q AS MODULATOR OF GPCR GALR2 AND USES THEREOF[2014/17]
French:NEUROPEPTIDE Q UTILISÉ COMME MODULATEUR DE GPCR GALR2 ET SES UTILISATIONS[2014/17]
Former [2013/32]NEUROPEPTID Q ALS GPCR-GALR2-MODULATOR UND SEINE VERWENDUNG
Former [2013/32]NEUROPEPTIDE Q AS MODULATOR OF GPCR GALR2 AND USES THEREOF
Former [2013/32]NEUROPEPTIDE Q UTILISÉ COMME MODULATEUR DE GPCR GALR2 ET SES UTILISATIONS
Entry into regional phase29.04.2013National basic fee paid 
29.04.2013Designation fee(s) paid 
29.04.2013Examination fee paid 
Examination procedure29.04.2013Examination requested  [2013/32]
25.03.2014Communication of intention to grant the patent
15.07.2014Fee for grant paid
15.07.2014Fee for publishing/printing paid
15.07.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.03.2014
Opposition(s)28.05.2015No opposition filed within time limit [2015/32]
Fees paidRenewal fee
30.09.2013Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.09.2011
AL27.08.2014
AT27.08.2014
BE27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
MK27.08.2014
MT27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
TR27.08.2014
IE23.09.2014
LU23.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
[2018/46]
Former [2018/31]HU23.09.2011
AT27.08.2014
BE27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
MK27.08.2014
MT27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
TR27.08.2014
IE23.09.2014
LU23.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2017/46]HU23.09.2011
AT27.08.2014
BE27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
MT27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
TR27.08.2014
IE23.09.2014
LU23.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2016/33]HU23.09.2011
AT27.08.2014
BE27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
MT27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
IE23.09.2014
LU23.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2016/32]HU23.09.2011
AT27.08.2014
BE27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
MT27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
IE23.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2016/28]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
MT27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
IE23.09.2014
BE30.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2016/22]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
SM27.08.2014
IE23.09.2014
BE30.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/51]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SI27.08.2014
SK27.08.2014
IE23.09.2014
BE30.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/37]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SK27.08.2014
IE23.09.2014
BE30.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/30]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SK27.08.2014
BE30.09.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/27]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
MC27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SK27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/24]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
NL27.08.2014
PL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SK27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/23]AT27.08.2014
CY27.08.2014
CZ27.08.2014
DK27.08.2014
EE27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
NL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
SK27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/22]AT27.08.2014
CY27.08.2014
DK27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
IT27.08.2014
LT27.08.2014
LV27.08.2014
NL27.08.2014
RO27.08.2014
RS27.08.2014
SE27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/16]AT27.08.2014
CY27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
LT27.08.2014
LV27.08.2014
NL27.08.2014
RS27.08.2014
SE27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/12]AT27.08.2014
CY27.08.2014
ES27.08.2014
FI27.08.2014
HR27.08.2014
LT27.08.2014
LV27.08.2014
RS27.08.2014
SE27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
IS27.12.2014
PT29.12.2014
Former [2015/11]CY27.08.2014
ES27.08.2014
FI27.08.2014
LT27.08.2014
SE27.08.2014
BG27.11.2014
NO27.11.2014
GR28.11.2014
PT29.12.2014
Former [2015/10]ES27.08.2014
FI27.08.2014
LT27.08.2014
SE27.08.2014
BG27.11.2014
NO27.11.2014
Former [2015/09]FI27.08.2014
LT27.08.2014
SE27.08.2014
Former [2015/08]LT27.08.2014
Cited inInternational search[A]US5972624  (SMITH KELLI E [US], et al) [A] 1-17 * claims 1-6 *
 [A]  - WANG S ET AL, "MOLECULAR CLONING AND PHARMACOLOGICAL CHARACTERIZATION OF A NEW GALANIN RECEPTOR SUBTYPE", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, (19970101), vol. 52, ISSN 0026-895X, pages 337 - 343, XP002942077 [A] 1-17 * abstract * * page 338, column 1, paragraph 5 - column 2, paragraph 1 * * figures 3-5; table 1 *
by applicantWO02096934
 US2005221359
 US5919649
 US5888819
 US6004744
 US6013431
 US4873191
 FR2593827
    - HABERT-ORTOLI ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 9780 - 9783
    - BURGEVIN ET AL., J. MOL. NEUROSCI., (1995), vol. 6, pages 33 - 41
    - HOWARD ET AL., FEBS LETTS., (1997), vol. 405, pages 285 - 290
    - SMITH ET AL., J. BIOL. CHEM., vol. 272, pages 24612 - 24616
    - WANG ET AL., MOL. PHARMACOL., (1997), vol. 52, pages 337 - 343
    - WANG ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 31949 - 31953
    - AHMAD ET AL., ANN. N. Y. ACAD. SCI., (1998), vol. 863, pages 108 - 119
    - BLOOMQUIST ET AL., BIOPHYS. RES.COMMUN., (1998), vol. 243, pages 474 - 479
    - KOLAKOWSKI ET AL., J. NEUROCHEM., (1998), vol. 71, pages 2239 - 2251
    - SMITH ET AL., J. BIOL. CHEM., (1998), vol. 273, pages 23321 - 23326
    - SMITH ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 24612 - 24616
    - O'DONNELL ET AL., J. COMP. NEUROL., (1999), vol. 409, pages 469 - 481
    - WATERS, KRAUSE, NEUROSCIENCE, (2000), vol. 95, pages 265 - 271
    - HAWES ET AL., J. COMP. NEUROL., (2004), vol. 479, pages 410 - 423
    - TATEMOTO ET AL., FEBS LETT., (1983), vol. 164, pages 124 - 128
    - FISONE ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 7339 - 7343
    - MISANE ET AL., EUR. J. NEUROSCI., (1998), vol. 10, pages 1230 - 1240
    - PIERIBONE ET AL., NEUROSCI., (1995), vol. 64, pages 861 - 876
    - HOKFELT ET AL., ANN. N. Y. ACAD. SCI., (1998), vol. 863, pages 252 - 263
    - KINNEY ET AL., J. NEUROSCI., (1998), vol. 18, pages 3489 - 3500
    - ZINI ET AL., EUR. J. PHARMACOL., (1993), vol. 245, pages 1 - 7
    - MASTROPAOLO ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 85, pages 9841 - 9845
    - SAKURAI ET AL., NEUROSCI. LETT., (1996), vol. 212, pages 21 - 24
    - KINNEY ET AL., NEUROBIOL. LEARN. MEM., (2009), vol. 92, pages 429 - 438
    - MAZARATI ET AL., BRAIN RES., (1992), vol. 589, pages 164 - 166
    - WIESENFELD ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, no. 3, pages 334 - 3337
    - CRAWLEY, CELL. MOL. LIFE SCI., (2008), vol. 65, pages 1836 - 1841
    - HOKFELT ET AL., NEUROSCI. LETT., (1987), vol. 83, pages 217 - 220
    - VILLAR ET AL., NEUROSCI., (1990), vol. 36, pages 181 - 199
    - CORTES ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 7742 - 7746
    - HENDERSON, NEUROSCI. LETT., (1999), vol. 266, pages 41 - 44
    - BRECHT ET AL., BRAIN RES. MOL. BRAIN RES., (1997), vol. 48, pages 7 - 16
    - WERNER, COVENAS, INT J NEUROSCI., (2010), vol. 120, pages 455 - 70
    - WANG, GUSTAFSON, DRUG NEWS PERSPECT., (1998), vol. 11, pages 458 - 68
    - HABERT-ORTOLI ET AL., PROC. NATL. ACAD. SCI. U S A., (1994), vol. 91, pages 9780 - 9783
    - SMITH, J. BIOL. CHEM., (1998), vol. 273, pages 23321 - 23326
    - FATHI ET AL., BRAIN RES MOL BRAIN RES., (1997), vol. 51, pages 49 - 59
    - HOWARD ET AL., FEBS LETT., (1997), vol. 405, pages 285 - 290
    - WANG ET AL., MOL PHARMACOL., (1997), vol. 52, pages 337 - 343
    - WITTAU ET AL., ONCOGENE, (2000), vol. 19, pages 4199 - 4209
    - KANAZAWA ET AL., EXPERT OPIN. THER. TARGETS., (2010), vol. 14, pages 289 - 302
    - WU ET AL., EUR. J. PHARMACOL., (2003), vol. 482, pages 133 - 137
    - SAAR ET AL., PROC. NATL. ACAD. SCI. U. S. A., (2002), vol. 99, pages 7136 - 7141
    - ZACHARIOU ET AL., PROC. NATL. ACAD. SCI. U. S. A., (2003), vol. 100, pages 9028 - 9033
    - ABRAMOV ET AL., NEUROPEPTIDES, (2003), vol. 38, pages 55 - 61
    - MAZARATI ET AL., J PHARMACOL EXP THER., (2006), vol. 318, pages 700 - 708
    - LIU ET AL., PROC NATL ACAD SCI USA., (2001), vol. 98, pages 9960 - 9964
    - LU ET AL., NEUROPEPTIDES, (2005), vol. 39, pages 143 - 146
    - MAZARATI ET AL., J NEUROCHEM, (2005), vol. 95, pages 1495 - 1503
    - WANG ET AL., BIOCHEMISTRY, (1998), vol. 37, pages 6711 - 6717
    - BRANCHEK ET AL., TRENDS PHARMACOL SCI, (2000), vol. 21, pages 109 - 117
    - LU ET AL., NEUROPEPTIDES., (2005), vol. 39, pages 143 - 146
    - LU ET AL., PROC NATL ACAD SCI USA, (2005), vol. 102, pages 874 - 879
    - HOKFELT ET AL., LANCET NEUROL., (2003), vol. 2, pages 463 - 472
    - CHANG ET AL., NAT. NEW. BIOL., (1971), vol. 232, pages 86 - 87
    - HOKFELT ET AL., NATURE, (1980), vol. 284, pages 525 - 521
    - KRAMER ET AL., SCIENCE, (1998), vol. 281, pages 1640 - 1645
    - MIRABEAU ET AL., GENOME RES., (2007), vol. 17, pages 320 - 327
    - TAJIB ET AL., NATURE BIOTECHNOLOGY, (2000), vol. 18, pages 649 - 654
    - HUBBARD, COHN, J. CELL BIOL., (1975), vol. 64, pages 461 - 479
    - SALAMON ET AL., BIOPHYS. J., (1996), vol. 71, pages 283 - 294
    - MISHIZUMA, NAGATA, NUCL. ACIDS RES., (1990), vol. 18, page 5322
    - GHATTAS ET AL., MOL. CELL. BIOL., (1991), vol. 11, pages 5848 - 5859
    - KJELSBERG ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 1430 - 1433
    - MCWHINNEY ET AL., J. BIOL. CHEM., (2000), vol. 275, pages 2087 - 2097
    - REN ET AL., J. BIOL. CHEM., (1993), vol. 268, pages 16483 - 16487
    - PARMA ET AL., NATURE, (1993), vol. 365, pages 649 - 651
    - SALAMON ET AL., BIOPHYS J., vol. 71, pages 283 - 294
    - BIOPHYS. J., (2001), vol. 80, pages 1557 - 1567
    - TRENDS BIOCHEM. SCI., (1999), vol. 24, pages 213 - 219
    - SARRIO ET AL., MOL. CELL. BIOL., (2000), vol. 20, pages 5164 - 5174
    - TRAYNOR, NAHORSKI, MOL. PHARMACOL., (1995), vol. 47, pages 848 - 854
    - STABLES ET AL., ANAL. BIOCHEM., (1997), vol. 252, pages 115 - 126
    - DETHEUX ET AL., J. EXP. MED., (2000), vol. 192, pages 1501 - 1508
    - KENIMER, NIRENBERG, MOL. PHARMACOL., (1981), vol. 20, pages 585 - 591
    - HORTON, BAXENDALE, METHODS MOL. BIOL., (1995), vol. 41, pages 91 - 105
    - RUDOLPH ET AL., J. BIOL. CHEM., (1999), vol. 274, pages 11824 - 11831
    - KIKKAWA ET AL., J. BIOL. CHEM., (1982), vol. 257, page 13341
    - PINNA, RUZZENE, BIOCHEM. BIOPHYS. ACTA., (1996), vol. 1314, pages 191 - 225
    - FINK ET AL., PROC. NATL. ACAD. SCI., (1988), vol. 85, pages 6662 - 6666
    - MONTMINY ET AL., PROC. NATL. ACAD. SCI., (1986), vol. 8, no. 3, pages 6682 - 6686
    - COMB ET AL., NATURE, (1986), vol. 323, pages 353 - 356
    - SHORT ET AL., J. BIOL. CHEM., (1986), vol. 261, pages 9721 - 9726
    - HAFNER, BIOSENS. BIOELECTRON., (2000), vol. 15, pages 149 - 158
    - COSTAGLIOLA ET AL., J. CLIN. INVEST., (2000), vol. 105, pages 803 - 811
    - KOHLER, MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - KOZBAR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, page 72
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1985), pages 77 - 96
    - PALMITER, BRINSTER, ANN. REV. GENET., (1986), vol. 20, pages 465 - 499
    - HUSZAR ET AL., CELL, (1997), vol. 88, page 131
    - OHKI-HAMAZAKI ET AL., NATURE, (1997), vol. 390, page 165
    - WAGNER ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, page 4323
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.